Clinical Trials Logo

Conjunctivitis clinical trials

View clinical trials related to Conjunctivitis.

Filter by:

NCT ID: NCT00831025 Completed - Clinical trials for Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen

OLEA
Start date: January 2008
Phase: Phase 3
Study type: Interventional

The objective of this trial is to assess the clinical efficacy of a modified allergen extract of Olea europaea pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis (with or without episodic asthma) induced by hypersensitivity to olea europaea pollen, evaluating the Score regarding Symptoms and consumption of the medication.

NCT ID: NCT00824447 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Long-term Efficacy and Safety Study With Oralgen Grass Pollen

Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This study is designed to give additional information on the efficacy, safety and local effects (tolerability) of a dose of sublingual immunotherapy administered once a day, during a second grass pollen season.

NCT ID: NCT00818805 Completed - Clinical trials for Allergic Conjunctivitis

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

Start date: July 2008
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.

NCT ID: NCT00818181 Completed - Rhinoconjunctivitis Clinical Trials

Open Label Safety Study of a Birch Pollen Allergen Extract

Start date: June 2008
Phase: Phase 2
Study type: Interventional

This trial is performed to assess safety of a sublingual birch pollen extract.

NCT ID: NCT00813046 Completed - Clinical trials for Seasonal Allergic Rhinoconjunctivitis

Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the oral administration of grass pollen peptides to treat allergic rhinitis is safe and well tolerated.

NCT ID: NCT00812799 Active, not recruiting - Clinical trials for Allergic Rhinoconjunctivitis

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.

NCT ID: NCT00803244 Completed - Primary Disease Clinical Trials

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma)

Start date: January 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of sublingual tablets of grass pollen allergen extract when initiated 2 months before the grass pollen season compared with placebo for reduction of rhinoconjunctivitis symptoms and rescue medication usage.

NCT ID: NCT00800332 Completed - Rhinoconjunctivitis Clinical Trials

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.

NCT ID: NCT00798577 Completed - Clinical trials for Bacterial Conjunctivitis

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

Start date: October 2008
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to investigate the initial antibiotic effects in the treatment of bacterial conjunctivitis symptoms in subjects one year of age and older.

NCT ID: NCT00783198 Completed - Conjunctivitis Clinical Trials

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Start date: September 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season.